The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

Completed · Phase 2

Conditions studied: Depressive Disorder, Major

In brief

To determine if the NMDA antagonist, CP-101,606, is effective for depression

Key facts

Study ID

NCT00163059

Run by

Pfizer

People needed

30

Starts

2004-05-01

Expected to finish

2005-12-01

Last updated by the study team

2006-09-22

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary DSM-IV diagnosis of MDD

You may not qualify if…

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Where it is running

• Pfizer Investigational Site — Wichita, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.